


iCHOR Vascular

Innovating Simplified Thrombectomy Solutions



Peripheral vascular occlusions have traditionally been treated using two methods: open surgery or thrombolytic drugs (lytics). While somewhat effective, both carry significant risks. Surgical thrombectomy is a procedure that often leads to surgical complications such as hematoma, blood loss, vessel trauma, and prolonged recovery. Lytic therapy is an easier therapy to prescribe, however it increases the risk of severe bleeding events, including intracranial hemorrhage, is limited for qualified patients, and presents prolonged delivery and recovery time which is extremely costly. Surgical and drug complications present risk, and today's peripheral interventional solutions continue to have shortcomings while costs skyrocket. Physicians have long sought a safer, more efficient alternative that addresses today's shortcomings

while hospitals and our healthcare system continue to seek treatment options that address the economics in treating peripheral occlusions.

iCHOR Vascular was founded to address this gap. Co-founded by interventional radiologist Dr. Troy Long and medical device veteran Tim Blair, the company is transforming mechanical thrombectomy by returning to the fundamental parameters of surgical thrombectomy. Rather than building on existing technologies like aspiration and metal coring, iCHOR drew inspiration from the proven surgical Fogarty balloon technique, known for its effectiveness in surgical clot removal. The team modernized this surgical technique into a minimally invasive solution with the iSWEEP platform.

"Our goal was to bring the predictability and reliability of surgical clot removal into a minimally invasive system," says Blair, CEO of iCHOR. "Physicians understand how a compliant balloon works, we simply wanted to give them that same control without the surgical complications. Patients can avoid drug and surgical complications and go home sooner which is good for the patient, the treating physician, the hospital ICUs, and our healthcare system."

A Surgical Concept, Reimagined for Endovascular Care

The iSWEEP system offers circumferential wall apposition, enabling a compliant balloon to engage the clot along the entire vessel wall—something that aspiration and other systems fail to achieve consistently. The iCHOR iSWEEP systems have recently demonstrated quick procedure times, no adverse events, no blood loss, and no post-procedure thrombotic issues at 30 days. The iCHOR systems completely eliminate the need for thrombolytic agents, surgery, and because there is no capital equipment; many of these patients are now being treated in same-day surgery settings.

Tailored to the complexities of peripheral vasculature, the iSWEEP systems are designed to effectively handle both arterial and venous thrombus. Many patients present with long clot segments in tortuous anatomy—areas where traditional aspiration or power-based systems struggle. The iSWEEP catheter navigates large and small vessel areas with ease, utilizing a balloon-based design that gently sweeps the clot toward a guide sheath for safe removal. All of this replicates the elements of an open surgery but without a cut down on the skin or a vessel.

“

Our goal was to bring the predictability and reliability of surgical clot removal into a minimally invasive system

”

The iSWEEP family includes two specifically tailored devices: iART, a 7F system optimized for arterial clot removal, and iDVT, a 14F system designed for venous clot removal. Both devices leverage the same innovative balloon-based design, offering physicians a versatile and reliable solution for treating both arterial and venous thrombotic conditions with a single device, ensuring precision and efficiency across varying types of morphology and anatomy.

One of the standout features of the iSWEEP system is its ease of use. Unlike many thrombectomy systems that require complex setups, multiple device exchanges, and substantial capital investment, iSWEEP is designed to be intuitive and integrate seamlessly into the physician's workflow. Having everything in a single disposable package with no need for big capital machines saves time and minimizes cognitive burden, especially in high-pressure clinical environments. It reduces practitioner and staff fatigue and allows them to focus on delivering optimal patient care that is intuitive. Open the iCHOR kit and treat the patient!

Physicians who have used the iSWEEP system have quickly adapted to its design. The balloon-based

mechanism is straightforward to control because it's the same mechanism of action used in surgical thrombectomy. The system's streamlined setup ensures that practitioners can perform procedures more efficiently and confidently. Physicians will be able to treat arterial issues such as occluded SFA stents, organized thrombus above the knee, vascular occlusions in the tibial branches below the knee, and even vascular debris logged near the ankle ALL with the same 7F iART system. Equally, physicians can safely treat venous occlusion just above the popliteal vein, common femoral vein, and iliac disease ALL with the same 14F iDVT system. It should be noted that many of these patients can now be treated in same-day surgery and office-based labs because of advances like iCHOR Vascular.



Building a Platform for the Future of Vascular Intervention

iCHOR's vision extends beyond lower extremity reperfusion. With first-in-human cases underway and promising early feedback, the company is poised to reshape the treatment of lower extremity peripheral vascular disease in both Hospital and Same Day Surgical settings, but also an eye on the massive dialysis market. Managing fistulae and grafts for dialysis patients is poorly served and iCHOR is currently moving its platform forward as a low-cost solution for this US \$1B underserved market.

As iCHOR advances toward broader commercialization, its mission is to make mechanical clot removal safer, more predictable, and more accessible. The company's innovation offers a minimally invasive alternative for patients and physicians to remove deadly clots and obstructions from the vascular system. By replicating surgical wisdom into a scalable, minimally invasive solution, iCHOR is setting a new standard in thrombectomy—empowering vascular specialists to improve patient outcomes while addressing the massive economic challenges this disease has on our health system. 